Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
03/2014
03/25/2014CA2675117C Iron-carbohydrate complex compounds with at least 2 wt% of total iron as iron(ii)
03/25/2014CA2668045C Peptide chimeric molecules having antiviral properties against viruses of the flaviviridae family
03/25/2014CA2617660C Multi-drug ligand conjugates
03/25/2014CA2565247C Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates
03/25/2014CA2524124C Methods for treating cancer using an immunotoxin
03/25/2014CA2524094C Low sodium solution
03/25/2014CA2507018C Materials and methods for preventing and treating microbe-mediated epithelial disorders
03/25/2014CA2494677C Derivatives of monosaccharides for drug discovery
03/25/2014CA2445826C Treatment and diagnosis of macrophage mediated disease
03/20/2014WO2014043693A1 Oral formulations of angiotensin
03/20/2014WO2014043625A1 Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
03/20/2014WO2014043618A1 Process for preparing therapeutic nanoparticles
03/20/2014WO2014043304A1 Topical compositions and methods of use
03/20/2014WO2014043291A1 Double-stranded nucleic acid compounds
03/20/2014WO2014043084A1 Polymer-polymer composite nanoassemblies and applications thereof
03/20/2014WO2014042922A1 Low molecular weight branched polyamines for delivery of biologically active materials
03/20/2014WO2014042921A1 Composite hydrogels for delivery of biologically active materials
03/20/2014WO2014042920A1 Branched polyamines for delivery of biologically active materials
03/20/2014WO2014042790A1 Antimicrobial alcoholic foamable compositions
03/20/2014WO2014042604A1 Clindamycin phosphate, salicylic acid and tea tree oil combinations
03/20/2014WO2014042463A1 Synthetically designed extracellular microenvironment
03/20/2014WO2014042450A1 Targeted drug delivery system for poorly soluble drug
03/20/2014WO2014042250A1 Drug-containing ultrafine fiber and utilization thereof
03/20/2014WO2014042142A1 Surface-modified iron oxide particles for cancer cauterization
03/20/2014WO2014041551A1 Formulation comprising imatinib as oral solution
03/20/2014WO2014041544A1 Immunoparticles and methods of generating and using same
03/20/2014WO2014041517A2 Dendrimers, conjugates and methods thereof
03/20/2014WO2014041505A1 Cell penetrating peptides
03/20/2014WO2014041427A1 A pharmaceutical composition comprising a solid nanoparticle and at least an antigen for the treatment against an intracellular pathogenic agent
03/20/2014WO2014041126A1 Method for marking or immobilizing a target structure
03/20/2014WO2014041087A1 Muscle secretome and uses thereof
03/20/2014WO2014041071A1 Semifluorinated alkane compositions
03/20/2014WO2014041015A1 Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it.
03/20/2014WO2014040994A1 Compositions comprising peg and ascorbate
03/20/2014WO2014040921A1 A pharmaceutical composition
03/20/2014WO2014040752A1 Receptor ligand linked cytotoxic molecules
03/20/2014WO2014040548A1 Metoprolol sustained-release drug and preparation method therefor
03/20/2014WO2014040228A1 Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it
03/20/2014WO2014017845A3 A liquid formulation of long acting insulinotropic peptide conjugate
03/20/2014WO2014004719A3 Chimeric peptide comprising an extracellular matrix protein together with an|antimicrobial peptide for use as a scaffold in wound dressing
03/20/2014WO2013190292A3 Novel process for preparation of antibody conjugates and novel antibody conjugates
03/20/2014WO2013140265A3 Fertility enhancing agent
03/20/2014WO2013126746A3 Dll3 modulators and methods of use
03/20/2014US20140081005 Antibody-drug conjugates
03/20/2014US20140080922 Polypeptide Based Block Copolymer and the Process for the Preparation Thereof, and the Polymer Micelles Using the Same
03/20/2014US20140080921 Biodisintegrable medical devices
03/20/2014US20140080918 Therapeutic solution concentrate
03/20/2014US20140080914 Aqueous acrylamide solution, stabilizer for aqueous acrylamide solution, and stabilization method for aqueous acrylamide solution
03/20/2014US20140080913 Sensory-Specific Local Anesthesia and Prolonged Duration Local Anesthesia
03/20/2014US20140080912 Suspension Pharmaceutical Formulations Comprising Low Melting Propionic Acid Derivative Particles
03/20/2014US20140080911 Polymeric Adhesive Matrix with Salified Carboxylic Groups for Transdermal Use
03/20/2014US20140080897 Hyaluronic acid-nucleic acid conjugate and composition for nucleic acid delivery containing the same
03/20/2014US20140080864 Pharmacetuical composition comprising drotaverine
03/20/2014US20140080841 Chemical Permeation Enhancers Enhance Nerve Blockade by Toxins
03/20/2014US20140080836 Methods and compositions for treating or preventing erythema
03/20/2014US20140080812 Novel parenteral carbamazepine formulation
03/20/2014US20140080766 Compositions and methods for macromolecular drug delivery
03/20/2014US20140080760 Combination therapy for treatment of cancer
03/20/2014US20140079804 Compositions and methods for treatment of infections
03/20/2014US20140079796 Sustained Release Oral Dosage Forms Comprising Low Melting Propionic Acid Derivative Particles
03/20/2014US20140079795 Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance
03/20/2014US20140079794 Gelatin particle and use thereof, and device for administration of physiologically active substance
03/20/2014US20140079793 Combinations and modes of administration of therapeutic agents and combination therapy
03/20/2014US20140079791 Pharmaceutical preparations containing highly volatile silicones
03/20/2014US20140079789 Bioglass with Glycosaminoglycans
03/20/2014US20140079788 Methods of treatment of pancreatic cancer
03/20/2014US20140079786 Fiber Spheres
03/20/2014US20140079778 Pharmaceutical Formulations Including An Amine Compound
03/20/2014US20140079773 Encapsulating liposomes
03/20/2014US20140079763 Methods and systems for treatment of inflammatory diseases with nitric oxide
03/20/2014US20140079754 Microfabricated nanopore device for sustained release of therapeutic agent
03/20/2014US20140079753 Bmp binding peptides
03/20/2014US20140079743 Coatings of acrylamide-based copolymers
03/20/2014US20140079738 Self-gelatinizable nucleic acid
03/20/2014US20140079730 Composition comprising vlp and amyloid beta peptide
03/20/2014US20140079728 Adjuvanting material
03/20/2014US20140079722 Extracellular targeted drug conjugates
03/20/2014US20140079721 Compositions and methods for the diagnosis and treatment of tumor
03/20/2014US20140079720 Inhibitors of extracellular hsp90
03/20/2014US20140079700 Method for promoting bone growth using activin-actriia antagonists
03/20/2014US20140079696 Method of increasing the effect of an activated-potentiated form of an antibody
03/20/2014US20140079679 Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
03/20/2014US20140079674 Spider silk proteins and methods for producing spider silk proteins
03/20/2014US20140079663 Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
03/20/2014US20140079642 Nanoparticles based for dermal and systemic delivery of drugs
03/20/2014US20140079638 Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases
03/20/2014US20140079636 Targeted therapeutics
03/20/2014US20140079630 Carbon nanotubes for imaging and drug delivery
03/20/2014US20140079629 Class I Anti-CEA Antibodies and Uses Thereof
03/19/2014EP2708570A1 Gelatin Particle and Use Thereof, and Device for Administration of Physiologically Active Substance
03/19/2014EP2708561A2 Bio-pin
03/19/2014EP2708264A2 Cosmetic two component preparation
03/19/2014EP2708243A1 Receptor ligand linked cytotoxic molecules
03/19/2014EP2708237A1 Pharmaceutical composition for its use in the preventive treatment of infections caused by an intracellular pathogen, more particularly Toxoplasma gondii
03/19/2014EP2708229A1 Non-aqueous patch
03/19/2014EP2708225A1 DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin
03/19/2014EP2707419A2 Reversibly crosslinked micelle systems
03/19/2014EP2707129A1 Edible liquid filled polysaccharide capsules
03/19/2014EP2707035A1 Pretargeting kit for imaging or therapy comprising a trans - cyclooctene dienophile and a diene
03/19/2014EP2707033A1 Targeted polymeric conjugates and uses thereof
1 ... 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 ... 1712